Back to Trials
NCT05788016NARecruiting

Developing an Opioid Taper Intervention Before Total Joint Arthroplasty

University of Alabama at Birmingham

Start Date

1/10/2024

Completion Date

7/1/2027

Summary

The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks * currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months * have a reliable telephone number for contact * speaks English Exclusion Criteria: * Taking opioid medications that include: * Buprenorphine * Methadone * Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine) * Transdermal formations of opioid pain medications (e.g., fentanyl patches)

Interventions

BEHAVIORAL

opioid taper

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Arthritis KneeArthritis HipChronic Pain

Locations

UAB Hospital-Highlands

Birmingham, Alabama 35205

United States